Q2 2023 EPS Estimates for SenesTech, Inc. Lifted by Analyst (NASDAQ:SNES)

SenesTech, Inc. (NASDAQ:SNES – Get Rating) – Stock analysts at HC Wainwright raised their Q2 2023 EPS estimates for shares of SenesTech in a research report issued on Wednesday, May 24th. HC Wainwright analyst A. Dayal now expects that the company will post earnings per share of ($0.78) for the quarter, up from their previous estimate of ($0.86). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for SenesTech’s current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for SenesTech’s Q3 2023 earnings at ($0.85) EPS, Q4 2023 earnings at ($0.86) EPS, FY2023 earnings at ($3.81) EPS, FY2024 earnings at ($3.37) EPS, FY2025 earnings at ($2.81) EPS, FY2026 earnings at ($1.72) EPS and FY2027 earnings at ($0.67) EPS.

Separately, StockNews.com upgraded shares of SenesTech to a “sell” rating in a research note on Thursday.

SenesTech Stock Performance

SNES opened at $1.30 on Friday. SenesTech has a fifty-two week low of $1.02 and a fifty-two week high of $14.60. The firm has a 50-day moving average of $1.40 and a 200 day moving average of $2.27.

SenesTech (NASDAQ:SNES – Get Rating) last announced its quarterly earnings data on Thursday, May 11th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.51). The business had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.32 million. SenesTech had a negative net margin of 889.31% and a negative return on equity of 216.13%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in SenesTech stock. Armistice Capital LLC acquired a new stake in shares of SenesTech, Inc. (NASDAQ:SNES – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 72,130 shares of the company’s stock, valued at approximately $223,000. Armistice Capital LLC owned about 11.82% of SenesTech as of its most recent SEC filing.

SenesTech Company Profile

(Get Rating)

SenesTech, Inc engages in the development and commercialization of proprietary technology for the management of animal pest populations, primarily rat populations through fertility control. It offers its ContraPest product to residential, and commercial sectors such as animal, structural, and food markets.